Abstract 3337
Background
Family caregivers of cancer patients report high burden leading to poor emotional and physical health. Knowledge of predisposing factors could contribute to its prevention or early detection. The aim of this study was to identify the factors related to caregiver burden among caregivers of cancer patients.
Methods
90 cancer patients hospitalised in two oncological wards in Crete, Greece and their primary caregivers (PCs) were included in the study. They both provided their demographics, while PCs completed the Bakas Caregiving Outcomes Scale (BCOS), comprising 15 self-rated items (7-point response scale with reduced BCOS scores implying higher burden) and the Hospital Anxiety and Depression Scale (HADS), comprising 14 self-rated items in a 4-point scale (0-3).
Results
Most patients were male (52.2%) and most PCs were female (67.8%), aged 50 to 74 years old (52.2% and 54.4% respectively). The majority of PCs (44.3%) were spouses. The mean of burden using the BCOS was 56.7 (SD 10.9) (range 22-100), 75.6% experienced no burden (total score > 52.5), while 24.4% reported high burden (total score < 52.5). High level of anxiety (≥ 11) using the HADS was reported by 55.6% of PCs and high level of depression (≥ 11) by 20%. The correlations between BCOS and HAD-Anxiety (r=-0.401, p < 0.001) and BCOS and HAD-Depression (r=-0.402, p < 0.001) were negatively moderate. Older age PCs appear to experience higher burden (r=-0.278, p = 0.008) and depression (r = 0.372, p < 0.001), while the duration of caregiving also imposes more anxiety (r=-0.322, p = 0.002) and depression (r = 0.262, p = 0.013). On the other hand, depression correlates negatively with the educational background of both patients (r=-0.247, p = 0,019) and caregivers (r=-0.283, p = 0.007).
Conclusions
Primary caregiver anxiety, depression, age, the duration of caregiving and the patient and caregiver educational background are factors related to caregiver burden. Larger sample studies are needed to better identify the factors affecting caregiver burden.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1285 - Preliminary results of STELLAR-001, a dose escalation phase I study of the anti-C5aR, IPH5401, in combination with durvalumab in advanced solid tumors.
Presenter: Christophe Massard
Session: Poster Display session 3
Resources:
Abstract
3808 - GOLFIG chemo-immunotherapy in metastatic colorectal cancer (mCRC) patients: A fifteen year retrospective analysis
Presenter: Pierpaolo Correale
Session: Poster Display session 3
Resources:
Abstract
5677 - Immune correlates in peripheral blood samples in a preoperative window of opportunity randomized trial of nivolumab with or without tadalafil in resectable squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Larry Harshyne
Session: Poster Display session 3
Resources:
Abstract
4854 - Phase 1 evaluation of AB928, a novel dual adenosine receptor antagonist, combined with chemotherapy or AB122 (anti-PD-1) in patients (pts) with advanced malignancies
Presenter: John Powderly
Session: Poster Display session 3
Resources:
Abstract
4344 - Phase 1 Trial of CV301 in Combination with Anti-PD-1 Therapy in Non-squamous NSCLC
Presenter: Arun Rajan
Session: Poster Display session 3
Resources:
Abstract
4555 - Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumors: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts
Presenter: Henry Conter
Session: Poster Display session 3
Resources:
Abstract
3012 - Excellent CBR and Prolonged PFS in Non-Squamous NSCLC with Oral CA-170, an Inhibitor of VISTA and PD-L1
Presenter: Vivek Radhakrishnan
Session: Poster Display session 3
Resources:
Abstract
2536 - Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic (R/M) HPV-16+ cancers
Presenter: Christophe Le Tourneau
Session: Poster Display session 3
Resources:
Abstract
1845 - Induction of tumor-infiltrating functional CD8 positive cells and PD-L1 expression in esophageal cancer by S-588410
Presenter: Takashi Kojima
Session: Poster Display session 3
Resources:
Abstract
5043 - Comprehensive results of a Phase Ib study with a HER2/neu B-cell peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy show safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced gastric cancer
Presenter: Ursula Wiedermann
Session: Poster Display session 3
Resources:
Abstract